跳至主要内容
临床试验/NCT04131218
NCT04131218Unknown4 期

Pharmacokinetics and Pharmacodynamics of Sugammadex in Reversal of Vecuronium-induced Neuromuscular Blockade in Anesthesia Obese Patients Undergoing Bariatric Surgery

Guangzhou General Hospital of Guangzhou Military Command1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2019年7月16日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
发起方
入组人数
20
试验地点
1
主要终点
Plasma Concentration of Sugammadex

研究概览

简要总结

The purpose of this study is to illustrate pharmacokinetics and pharmacodynamics of sugammadex in reversal of vecuronium-induced neuromuscular blockade in anesthesia obese patients undergoing bariatric surgery.

详细描述

16 obese patients undergoing bariatric surgery were divided into 2 groups according to body mass index (BMI), including obese group (O group, n=8, 25≤BMI≤39.9kg/m²) and morbidly obese group (M group, n=8, BMI≥40kg/m²).

Vecuronium was continuous infusing to maintain moderate neuromuscular blockade during the laparoscopic surgery and stopped infusing after the laparoscopic procedure. A single dose administration of sugammadex (Sug) 2.0mg/kg according to ideal body weight (IBW) was given at the reappearance of the second twitch of the train-of-four (TOF) response.

On one hand, venous blood samples were obtained before administration of Sug and at 2, 3, 5, 10, 15, 20, 30, 60 minutes and 2, 4, 6, 8 hours after administration of Sug to determine plasma concentration of Sug using HPLC-MS. On the other hand, time from start of administration of Sug to recovery of TOF ratio to 0.9 and other clinical indicators were also recorded.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • ASA: Ⅰ~Ⅲ
  • BMI≥25kg/m²
  • Patients receiving bariatric surgery.

排除标准

  • Pregnant or lactating women
  • Neuromuscular diseases
  • Malignant hyperthermia or allergic history during general anesthesia
  • Drugs that react with rocuronium and vecuronium were taken

研究组 & 干预措施

Obese group

Experimental

n=8, 25≤BMI≤39.9kg/m²

干预措施: Sugammadex (Drug)

Morbidly obese group

Experimental

n=8, BMI≥40kg/m²

干预措施: Sugammadex (Drug)

结局指标

主要结局

Plasma Concentration of Sugammadex

时间窗: 0, 2, 3, 5, 10, 15, 20, 30, 60 minutes and 2, 4, 6, 8 hours

venous blood samples were obtained

Recovery Time and TOF ratio

时间窗: TOF ratio at 30, 60, 90, 120, 150 seconds after administration

time from start of administration of Sug to recovery of TOF ratio to 0.9 and other indicators

次要结局

未报告次要终点

研究者

发起方
Guangzhou General Hospital of Guangzhou Military Command
申办方类型
Other
责任方
Principal Investigator
主要研究者

bo xu

Clinical Professor

Guangzhou General Hospital of Guangzhou Military Command

研究点 (1)

Loading locations...

相似试验